Joep Lange | Academic Influence

Joep Lange's AcademicInfluence.com Rankings

Joep Lange

Philosophy

#7466

World Rank

#10686

Historical Rank

Logic

#4557

World Rank

#5867

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Joep Lange's Degrees

Doctorate Medicine University of Amsterdam

Why Is Joep Lange Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Joseph Marie Albert "Joep" Lange was a Dutch clinical researcher specialising in HIV therapy. He served as the president of the International AIDS Society from 2002 to 2004. He was a passenger on Malaysia Airlines Flight 17, which was shot down on 17 July 2014 over Ukraine.

(See a Problem?)

Joep Lange's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population (1992) (1146)
Persistent immune activation in HIV-1 infection is associated with progression to AIDS (2003) (788)
A randomized, double-blind trial comparing combinations of Nevirapine, Didanosine, and Zidovudine for HIV-infected patients: the INCAS trial (1998) (746)
Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates (1989) (669)
Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. (2003) (652)
Immunological abnormalities in human immunodeficiency virus (HIV)-infected asymptomatic homosexual men. HIV affects the immune system before CD4+ T helper cell depletion occurs. (1988) (486)
Increased cell division but not thymic dysfunction rapidly affects the T-cell receptor excision circle content of the naive T cell population in HIV-1 infection (2000) (452)
Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection (2000) (420)
Hypertension in Sub-Saharan Africa: Cross-Sectional Surveys in Four Rural and Urban Communities (2012) (393)
Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. (1992) (378)
Persistent HIV antigenaemia and decline of HIV core antibodies associated with transition to AIDS. (1986) (345)
Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. (2002) (343)
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years (2007) (336)
The spread, treatment, and prevention of HIV-1: evolution of a global pandemic. (2008) (301)
A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. (1998) (286)
Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. (2001) (282)
Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral- Therapy-Naive Patients Infected with HIV-1 (2004) (282)
Viral phenotype and immune response in primary human immunodeficiency virus type 1 infection. (1992) (279)
Suppression of plasma viral load below 20 copies/ml is required to achieve a long‐term response to therapy (1998) (264)
Declining incidence of AIDS dementia complex after introduction of zidovudine treatment. (1989) (239)
Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy. (1999) (233)
High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals (2001) (230)
Seroconversion for human herpesvirus 8 during HIV infection is highly predictive of Kaposi's sarcoma (1998) (212)
Antiretroviral drugs and the central nervous system. (1998) (202)
Numbers of CD4+ cells and the levels of core antigens of and antibodies to the human immunodeficiency virus as predictors of AIDS among seropositive homosexual men. (1988) (193)
Improvement of chronic diarrhoea in patients with advanced HIV‐1 infection during potent antiretroviral therapy (1998) (193)
A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients (2003) (190)
Mortality and progression to AIDS after starting highly active antiretroviral therapy (2003) (188)
CD4 Cell Counts of 800 Cells/mm3 or Greater After 7 Years of Highly Active Antiretroviral Therapy Are Feasible in Most Patients Starting With 350 Cells/mm3 or Greater (2007) (185)
Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons. (1999) (185)
Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting (2001) (184)
Protection against sexually transmitted diseases by granting sex workers in Thailand the choice of using the male or female condom: results from a randomized controlled trial (1998) (179)
Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine (1998) (176)
Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort (2004) (174)
Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study (1998) (173)
Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals (2003) (171)
Are Adverse Events of Nevirapine and Efavirenz Related to Plasma Concentrations? (2005) (171)
Distinct IgG recognition patterns during progression of subclinical and clinical infection with lymphadenopathy associated virus/human T lymphotropic virus. (1986) (168)
Predictors of rapid progression to AIDS in HIV-1 seroconverters. (1993) (167)
Antigenemia and antibody titers to core and envelope antigens in AIDS, AIDS-related complex, and subclinical human immunodeficiency virus infection. (1987) (162)
Durable Efficacy of Enfuvirtide Over 48 Weeks in Heavily Treatment-Experienced HIV-1-Infected Patients in the T-20 Versus Optimized Background Regimen Only 1 and 2 Clinical Trials (2005) (156)
Ongoing HIV dissemination during HAART (1999) (152)
Immunopathology as a result of highly active antiretroviral therapy in HIV-1-infected patients. (1999) (152)
Emergence of a Drug-Dependent Human Immunodeficiency Virus Type 1 Variant during Therapy with the T20 Fusion Inhibitor (2004) (147)
The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals (2000) (141)
Whither or Wither Microbicides? (2008) (139)
Lipodystrophy in HIV-1-positive patients is associated with insulin resistance in multiple metabolic pathways (2001) (139)
OKT3 and IL-2 Treatment for Purging of the Latent HIV-1 Reservoir in Vivo Results in Selective Long-Lasting CD4+ T Cell Depletion (2001) (137)
The effect of plasma drug concentrations on HIV‐1 clearance rate during quadruple drug therapy (1998) (134)
Functional T cell reconstitution and human immunodeficiency virus-1-specific cell-mediated immunity during highly active antiretroviral therapy. (1999) (133)
Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996–2001 (2003) (131)
Presentation and course of AIDS dementia complex: 10 years of follow‐up in Amsterdam, The Netherlands (1993) (129)
Risk of AIDS related complex and AIDS in homosexual men with persistent HIV antigenaemia. (1987) (124)
Efavirenz: a review (2007) (123)
Alternative multidrug regimen provides improved suppression of HIV‐1 replication over triple therapy (1998) (122)
Herpes zoster, immunological deterioration and disease progression in HIV‐1 infection (1995) (121)
The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a Phase I study (1992) (121)
Antiretroviral Treatment Simplification With Nevirapine in Protease Inhibitor‐Experienced Patients With HIV‐Associated Lipodystrophy: 1‐Year Prospective Follow‐Up of a Multicenter, Randomized, Controlled Study (2001) (120)
A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy. (1999) (115)
Nevirapine and Efavirenz Pharmacokinetics and Covariate Analysis in the 2Nn Study (2005) (115)
Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo. (1997) (113)
The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals. (1999) (112)
Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. INCAS Study Group. (1999) (112)
Conversion rate towards a syncytium-inducing (SI) phenotype during different stages of human immunodeficiency virus type 1 infection and prognostic value of SI phenotype for survival after AIDS diagnosis. (1999) (111)
HIV‐1 biological phenotype and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment (1992) (103)
GB virus C coinfection and HIV-1 disease progression: The Amsterdam Cohort Study. (2005) (103)
Overshoot of HIV‐1 viraemia after early discontinuation of antiretroviral treatment (1997) (103)
Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. The EuroGUidelines Group for HIV resistance. (2001) (101)
Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir (2000) (101)
No Treatment versus 24 or 60 Weeks of Antiretroviral Treatment during Primary HIV Infection: The Randomized Primo-SHM Trial (2012) (101)
Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine. (1996) (100)
Simultaneous quantitative determination of the HIV protease inhibitors amprenavir, indinavir, nelfinavir, ritonavir and saquinavir in human plasma by ion-pair high-performance liquid chromatography with ultraviolet detection. (1998) (95)
Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study. (2001) (90)
Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA Cohort (2002) (89)
HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy (2008) (88)
Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group. (1996) (87)
Patterns of T-cell repopulation, virus load reduction, and restoration of T-cell function in HIV-infected persons during therapy with different antiretroviral agents. (1997) (86)
Speed of progression to AIDS and degree of antibody response to accessory gene products of HIV‐1 (1990) (85)
Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study. (2008) (85)
Safety of Enfuvirtide in Combination With an Optimized Background of Antiretrovirals in Treatment-Experienced HIV-1-Infected Adults Over 48 Weeks (2005) (85)
Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy. (2006) (84)
The Development of Artificial Neural Networks to Predict Virological response to Combination HIV Therapy (2007) (83)
Implementation of an Antiretroviral Access Program for HIV-1-Infected Individuals in Resource-Limited Settings: Clinical Results From 4 African Countries (2007) (82)
Autoimmunity against blood cells in human immunodeficiency-virus (HIV) infection (1987) (82)
Treatment Failure of Nelfinavir-Containing Triple Therapy Can Largely Be Explained by Low Nelfinavir Plasma Concentrations (2003) (82)
Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs (2005) (82)
P Glycoprotein in Human Immunodeficiency Virus Type 1 Infection and Therapy (2004) (81)
Long-term quality of life outcomes in three antiretroviral treatment strategies for HIV-1 infection (2001) (81)
Integration of HIV and TB Services Results in Improved TB Treatment Outcomes and Earlier Prioritized ART Initiation in a Large Urban HIV Clinic in Uganda (2012) (79)
Markers for progression in HIV infection (1989) (76)
Decline of antibody reactivity to outer viral core protein p17 is an earlier serological marker of disease progression in human immunodeficiency virus infection than anti-p24 decline. (1987) (74)
Herpes simplex virus type 2 and other genital ulcerative infections as a risk factor for HIV-1 acquisition. (1990) (74)
State of Affairs of Tuberculosis in Prison Facilities: A Systematic Review of Screening Practices and Recommendations for Best TB Control (2013) (72)
Prevalence of Lipoatrophy and Mitochondrial DNA Content of Blood and Subcutaneous Fat in HIV-1-Infected Patients Randomly Allocated to Zidovudine- or Stavudine-Based Therapy (2003) (71)
High-dose nevirapine in previously untreated human immunodeficiency virus type 1-infected persons does not result in sustained suppression of viral replication. (1997) (70)
Dehydroepiandrosterone as predictor for progression to AIDS in asymptomatic human immunodeficiency virus-infected men. (1992) (70)
Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomized, double‐blind placebo‐controlled study (1994) (69)
A comparison of three computational modelling methods for the prediction of virological response to combination HIV therapy (2009) (68)
Therapeutic immune reconstitution in HIV-1-infected children is independent of their age and pretreatment immune status (2001) (68)
The impact of the M184V substitution in HIV‐1 reverse transcriptase on treatment response (2002) (68)
Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients. (2003) (68)
Effect of health insurance and facility quality improvement on blood pressure in adults with hypertension in Nigeria: a population-based study. (2014) (67)
Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine (2001) (67)
A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection. (2005) (66)
Toxicity and drug exposure in a quadruple drug regimen in HIV–1 infected patients participating in the ADAM study (2000) (65)
Reduction of the HIV-1-infected T-cell reservoir by immune activation treatment is dose-dependent and restricted by the potency of antiretroviral drugs (2000) (65)
Induction–maintenance antiretroviral therapy: proof of concept (1998) (65)
The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons. (2001) (62)
Quantitative determination of efavirenz (DMP 266), a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection. (1999) (62)
Peptide inhibitors of virus-cell fusion: enfuvirtide as a case study in clinical discovery and development. (2004) (61)
Nevirapine Plasma Concentrations and Concomitant Use of Rifampin in Patients Coinfected with HIV-1 and Tuberculosis (2005) (61)
Viral gene expression, antibody production and immune complex formation in human immunodeficiency virus infection. (1987) (60)
Safety evaluation of nonoxynol‐9 gel in women at low risk of HIV infection (1998) (60)
A Retrospective, Cohort‐Based Survey of Patients Using Twice‐Daily Indinavir + Ritonavir Combinations: Pharmacokinetics, Safety, and Efficacy (2001) (59)
Simplifying Protease Inhibitor Therapy with Once‐Daily Dosing of Saquinavir Soft‐Gelatin Capsules/Ritonavir (1600/100 mg): HIVNAT 001.3 Study (2002) (59)
Antigen-driven CD4+ T cell and HIV-1 dynamics: residual viral replication under highly active antiretroviral therapy. (1999) (59)
Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir (2006) (58)
Antibody response to the viral negative factor (nef) in HIV-1 infection: a correlate of levels of HIV-1 expression. (1989) (58)
Viral phenotype and T cell reactivity in human immunodeficiency virus type 1-infected asymptomatic men treated with zidovudine. (1993) (58)
Establishment of the CD4+ T-cell pool in healthy children and untreated children infected with HIV-1. (2004) (57)
Viral Load Levels Measured at Set-Point Have Risen Over the Last Decade of the HIV Epidemic in the Netherlands (2009) (56)
Effects of discontinuation of zidovudine treatment on zidovudine sensitivity of human immunodeficiency virus type 1 isolates (1993) (55)
Pharmacokinetics of Reduced-Dose Indinavir/Ritonavir 400/100 Mg Twice Daily in HIV-1-Infected Thai Patients (2005) (55)
Analysis of the effect of highly active antiretroviral therapy during acute HIV-1 infection on HIV-specific CD4 T cell functions (2005) (54)
Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group (1996) (52)
Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age. (2012) (52)
Is the male genital tract really a sanctuary site for HIV? Arguments that it is not. (2004) (51)
TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals. (2007) (51)
Is there a difference in the efficacy of peripartum antiretroviral regimens in reducing mother-to-child transmission of HIV in Africa? Ghent Group on HIV in Women and Children (2005) (51)
Virologic and Immunologic Response to Highly Active Antiretroviral Therapy in Indigenous and Nonindigenous HIV-1–Infected Patients in The Netherlands (2004) (51)
Treatment of HIV Infection (1996) (51)
Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA. (2000) (51)
Functional restoration of human immunodeficiency virus and Epstein‐Barr virus‐specific CD8+ T cells during highly active antiretroviral therapy is associated with an increase in CD4+ T cells (2002) (50)
Comparison of the plasma pharmacokinetics and renal clearance of didanosine during once and twice daily dosing in HIV‐1 infected individuals (1998) (49)
Perceptions of inhibitors and facilitators for adhering to hypertension treatment among insured patients in rural Nigeria: a qualitative study (2014) (49)
Appearance of predictors of disease progression in relation to the development of AIDS (1989) (48)
Complications of varicella zoster virus reactivation in HIV‐infected homosexual men (1996) (48)
Global threat from drug resistant HIV in sub-Saharan Africa (2012) (46)
Reduced prevalence of the CCR5 delta32 heterozygous genotype in human immunodeficiency virus-infected individuals with AIDS dementia complex. (1999) (46)
Pharmacokinetics of once-daily saquinavir hard-gelatin capsules and saquinavir soft-gelatin capsules boosted with ritonavir in HIV-1-infected subjects. (2003) (46)
Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy: Collaborative Analysis of Cohorts of HIV-1-Infected Patients (2007) (45)
Time to act: global apathy towards HIV/AIDS is a crime against humanity (2002) (45)
The immunomodulatory nutritional intervention NR100157 reduced CD4+ T-cell decline and immune activation: a 1-year multicenter randomized controlled double-blind trial in HIV-infected persons not receiving antiretroviral therapy (The BITE Study). (2013) (45)
Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals: a pharmacokinetic pilot study (2000) (45)
Criteria for Drugs Used in Pre-Exposure Prophylaxis Trials against HIV Infection (2006) (45)
Human immunodeficiency virus exanthem. (1990) (44)
Safety of long-term interruption of successful antiretroviral therapy: the ATHENA cohort study (2005) (44)
A Low Dose of Ritonavir‐Boosted Atazanavir Provides Adequate Pharmacokinetic Parameters in HIV‐1‐Infected Thai Adults (2009) (43)
Diagnostic value of specific IgM antibodies in primary HIV infection. (1988) (43)
Mitochondrial DNA and RNA increase in peripheral blood mononuclear cells from HIV-1-infected patients randomized to receive stavudine-containing or stavudine-sparing combination therapy. (2005) (43)
HTLV-III/LAV infection in nine children infected by a single plasma donor: clinical outcome and recognition patterns of viral proteins. (1986) (42)
Earlier Testing for HIV – How do we Prevent Late Presentation? (2010) (42)
DECLINE OF ANTIBODY REACTIVITY TO HIV CORE PROTEIN SECONDARY TO INCREASED PRODUCTION OF HIV ANTIGEN (1987) (42)
Pharmacokinetic study of saquinavir hard gel caps/ritonavir in HIV-1-infected patients: 1600/100 mg once-daily compared with 2000/100 mg once-daily and 1000/100 mg twice-daily. (2004) (41)
Stable Concentrations of Zidovudine, Stavudine, Lamivudine, Abacavir, and Nevirapine in Serum and Cerebrospinal Fluid during 2 Years of Therapy (2002) (41)
Efavirenz, in Contrast to Nevirapine, is Associated With Unfavorable Progesterone and Antiretroviral Levels When Coadministered With Combined Oral Contraceptives (2013) (41)
Highly active antiretroviral therapy with or without mycophenolate mofetil in treatment-naive HIV-1 patients (2004) (41)
Effects of Active Treatment Discontinuation in Patients With a CD4+ T-Cell Nadir Greater Than 350 Cells/mm3: 48-Week Treatment Interruption in Early Starters Netherlands Study (TRIESTAN) (2007) (40)
New antiretrovirals and new combinations. (1998) (40)
Low T-cell responsiveness to activation via CD3/TCR is a prognostic marker for acquired immunodeficiency syndrome (AIDS) in human immunodeficiency virus-1 (HIV-1)-infected men (1990) (40)
An open randomized controlled trial of zidovudine plus lamivudine versus stavudine plus lamivudine (1998) (40)
What policymakers should know about drug resistance and adherence in the context of scaling-up treatment of HIV infection (2004) (40)
Occult hepatitis B virus infection before and 1 year after start of HAART in HIV type 1-positive patients. (2005) (40)
Therapy for cytomegalovirus polyradieulomyelitis in patients with AIDS: treatment with ganciclovir (1990) (39)
TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen (2003) (39)
The power of simplicity (2003) (39)
Replication of a pre-existing resistant HIV-1 subpopulation in vivo after introduction of a strong selective drug pressure. (1996) (39)
Significant Decrease of Ethinylestradiol With Nevirapine, and of Etonogestrel With Efavirenz in HIV-Positive Women (2014) (39)
A study of the reliability, validity and responsiveness of the HIV Overview of Problems Evaluation System (HOPES) in assessing the quality of life of patients with AIDS and symptomatic HIV infection (1996) (38)
Late Entry to HIV Care Limits the Impact of Anti-Retroviral Therapy in the Netherlands (2008) (38)
Nelfinavir plasma concentrations are low during pregnancy. (2004) (38)
Effects of highly active antiretroviral therapy (HAART) on psychomotor performance in children with HIV disease (2006) (38)
HIV disease progression in a patient cohort treated via a clinical research network in a resource limited setting (2005) (38)
Selective inhibition of syncytium-inducing and nonsyncytium-inducing HIV-1 variants in individuals receiving didanosine or zidovudine, respectively. (1997) (37)
Longitudinal study on the Quality of Life of symptomatic HIV-infected patients in a trial of zidovudine versus zidovudine and interferon-alpha. (1993) (37)
Value of Different Assays for Detection of Human Cytomegalovirus (HCMV) in Predicting the Development of HCMV Disease in Human Immunodeficiency Virus-Infected Patients (2000) (37)
Low T cell reactivity to combined CD3 plus CD28 stimulation is predictive for progression to AIDS: correlation with decreased CD28 expression (1996) (37)
Failure to detect a non-B HIV-1 subtype by the HIV-1 Amplicor Monitor test, version 1.5: a case of unexpected vertical transmission. (2003) (37)
A randomized, dose-finding study with didanosine plus stavudine versus didanosine alone in antiviral-naive, HIV-infected Thai patients (2000) (36)
Interindividual variability of once-daily ritonavir boosted saquinavir pharmacokinetics in Thai and UK patients. (2005) (36)
Long-term Effectiveness of Combination Antiretroviral Therapy and Prevalence of HIV Drug Resistance in HIV-1–infected Children and Adolescents in Rwanda (2014) (36)
Autoimmunity against blood cells in human immunodeficiency‐virus (HIV) infection (1987) (35)
Once-Daily Highly Active Antiretroviral Therapy for HIV-Infected Children: Safety and Efficacy of an Efavirenz-Containing Regimen (2007) (35)
Carrier rate of zidovudine-resistant HIV-1: the impact of failing therapy on transmission of resistant strains (2001) (35)
Effects of recombinant human granulocyte colony‐stimulating factor on leucopenia in zidovudine‐treated patients with AIDS and AIDS related complex, a phase I/II study (1991) (34)
Long-term Experience With Combination Antiretroviral Therapy That Contains Nelfinavir for up to 7 Years in a Pediatric Cohort (2006) (34)
Prednisolone does not prevent hypersensitivity reactions in antiretroviral drug regimens containing abacavir with or without nevirapine (2001) (34)
Pharmacokinetics and short-term efficacy of a double-boosted protease inhibitor regimen in treatment-naive HIV-1-infected adults. (2008) (33)
Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors (2003) (33)
Efficacy of tenofovir disoproxil fumarate/ emtricitabine compared with emtricitabine alone in antiretroviral-naive HIV–HBV coinfection in Thailand (2010) (33)
Improved long-term suppression of HIV-1 replication with a triple-class multidrug regimen compared with standard of care antiretroviral therapy (2002) (33)
HIV-1 seroreversion in an HIV-1-seropositive patient treated during acute infection with highly active antiretroviral therapy and mycophenolate mofetil. (2004) (33)
NYVAC immunization induces polyfunctional HIV‐specific T‐cell responses in chronically‐infected, ART‐treated HIV patients (2012) (33)
Low risk of treatment failure after substitution of nevirapine for protease inhibitors among human immunodeficiency virus-infected patients with virus suppression. (2002) (33)
Decline in CD4+ cell numbers reflects increase in HIV-1 replication. (1988) (33)
Changes in body composition and mitochondrial nucleic acid content in patients switched from failed nucleoside analogue therapy to ritonavir-boosted indinavir and efavirenz. (2006) (33)
Transient lowering of the viral set point after temporary antiretroviral therapy of primary HIV type 1 infection. (2010) (32)
Limited Sampling Strategies for the Estimation of the Systemic Exposure to the HIV-1 Nonnucleoside Reverse Transcriptase Inhibitor Nevirapine (2001) (32)
Increasing Cerebrospinal Fluid Chemokine Concentrations Despite Undetectable Cerebrospinal Fluid HIV RNA in HIV‐1‐Infected Patients Receiving Antiretroviral Therapy (2000) (32)
Effect of Mycophenolate Mofetil on the Pharmacokinetics of Antiretroviral Drugs and on Intracellular Nucleoside Triphosphate Pools (2004) (32)
Efficacy and Durability of Nevirapine in Antiretroviral Drug Naïve Patients (2003) (32)
Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment. (2005) (32)
T-cell progenitor function during progressive human immunodeficiency virus-1 infection and after antiretroviral therapy. (2000) (32)
Pathogenesis of HIV and its implications for serodiagnosis and monitoring of antiviral therapy. (1987) (31)
The Discovery and Development of Antiretroviral Agents (2014) (31)
Penetration of the nucleoside analogue abacavir into the genital tract of men infected with human immunodeficiency virus type 1. (2001) (31)
Naturally HIV-1 seroconverters with lowest viral load have best prognosis, but in time lose control of viraemia. (2002) (31)
Immunization with recombinant p17/p24:Ty virus-like particles in human immunodeficiency virus-infected persons. (1996) (31)
Reconstitution of EBV Latent but Not Lytic Antigen-Specific CD4+ and CD8+ T Cells after HIV Treatment with Highly Active Antiretroviral Therapy 1 (2005) (31)
CC Chemokine Receptor 5 Δ32 and CC Chemokine Receptor 2 64I Polymorphisms Do Not Influence the Virologic and Immunologic Response to Antiretroviral Combination Therapy in Human Immunodeficiency Virus Type 1–Infected Patients (2002) (30)
Emerging themes for sensitivity training modules of African healthcare workers attending to men who have sex with men: a systematic review (2015) (30)
Quality of Life in Patients Treated with First-Line Antiretroviral Therapy Containing Nevirapine And/Or Efavirenz (2004) (30)
Analysis of the antigen- and mitogen-induced differentiation of B lymphocytes from asymptomatic human immunodeficiency virus-seropositive male homosexuals. Discrepancy between T cell-dependent and T cell-independent activation. (1987) (30)
Epstein-Barr virus infects B and non-B lymphocytes in HIV-1-infected children and adolescents. (2006) (29)
Hepatitis B Virus Prevalence and Vaccine Response in HIV-infected Children and Adolescents on Combination Antiretroviral Therapy in Kigali, Rwanda (2012) (29)
Saliva as an Alternative Body Fluid for Therapeutic Drug Monitoring of the Nonnucleoside Reverse Transcription Inhibitor Nevirapine (2001) (29)
The use of pharmacokinetically guided indinavir dose reductions in the management of indinavir-associated renal toxicity. (2006) (29)
Autoantibodies against peripheral blood cells appear early in HIV infection and their prevalence increases with disease progression (1990) (29)
The use of adult somatic cell nuclear transfer to preserve the last surviving cow of the enderby island cattle breed (1999) (29)
Long-Term Highly Active Antiretroviral Therapy in Chronic HIV-1 Infection: Evidence for Reconstitution of Antiviral Immunity (2006) (28)
HCV‐specific T‐cell responses in injecting drug users: evidence for previous exposure to HCV and a role for CD4+ T cells focussing on nonstructural proteins in viral clearance (2008) (28)
Immune response to HIV p24 core protein during the early phases of human immunodeficiency virus infection. (1991) (28)
Decline of HIV antigen levels in cerebrospinal fluid during treatment with low-dose zidovudine. (1988) (28)
Current problems and the future of antiretroviral drug trials. (1997) (28)
Pharmacokinetics of Nevirapine: Once-Daily Versus Twice-Daily Dosing in the 2NN Study (2005) (28)
T cell expansions in lymph nodes and peripheral blood in HIV-1-infected individuals: effect of antiretroviral therapy (2001) (28)
Steady‐State Pharmacokinetics of Twice‐Daily Dosing of Saquinavir Plus Ritonavir in HIV‐1‐Infected Individuals (2001) (28)
A community-based intervention for primary prevention of cardiovascular diseases in the slums of Nairobi: the SCALE UP study protocol for a prospective quasi-experimental community-based trial (2013) (27)
Costs of cardiovascular disease prevention care and scenarios for cost saving: a micro-costing study from rural Nigeria (2015) (26)
Examining the evidence on the causal effect of HAART on transmission of HIV using the Bradford Hill criteria (2013) (26)
Pharmacokinetic Profiles of Nevirapine and Indinavir in Various Fractions of Seminal Plasma (2001) (26)
Contribution of antibody response to recombinant HIV-1 gene-encoded products nef, rev, tat, and protease in predicting development of AIDS in HIV-1-infected individuals. (1991) (26)
Limited penetration of lopinavir into seminal plasma of HIV-1-infected men. (2002) (26)
Cardiovascular disease prevention in rural Nigeria in the context of a community based health insurance scheme: QUality Improvement Cardiovascular care Kwara-I (QUICK-I) (2011) (26)
Randomized study of intradermal compared to intramuscular hepatitis B vaccination in HIV-infected children without severe immunosuppression. (2011) (26)
Triple combinations: present and future. (1995) (26)
HAART for the HIV-infected employees of large companies in Africa (2006) (26)
Long-term voluntary counseling and testing (VCT) uptake dynamics in a multicountry HIV workplace program in sub-Saharan Africa (2010) (25)
High-dose interferon-alpha2a exerts potent activity against human immunodeficiency virus type 1 not associated with antitumor activity in subjects with Kaposi's sarcoma. (1997) (25)
Summary of the international consensus symposium on management of HIV, CMV and hepatitis virus infections. (1998) (25)
Concentrations of human immunodeficiency virus type 1 (HIV-1) RNA in cerebrospinal fluid after antiretroviral treatment initiated during primary HIV-1 infection. (2001) (25)
Pharmacokinetics of Indinavir/Ritonavir (800/100 mg) in Combination With Efavirenz (600 mg) in HIV‐1‐Infected Subjects (2003) (25)
Distinct changes in HIV type 1 RNA versus p24 antigen levels in serum during short-term zidovudine therapy in asymptomatic individuals with and without progression to AIDS. (1995) (25)
Discordant responses during antiretroviral therapy: role of immune activation and T cell redistribution rather than true CD4 T cell loss. (2002) (25)
Seizing the opportunity to capitalise on the growing access to HIV treatment to expand HIV prevention (2004) (25)
Plasma concentrations of generic lopinavir/ritonavir in HIV type-1-infected individuals (2009) (24)
Cerebrospinal fluid β2-microglobulin, monocyte chemotactic protein-1, and soluble tumour necrosis factor α receptors before and after treatment with lamivudine plus zidovudine or stavudine (2000) (24)
steady-state Pharmacokinetics of Twice-daily Dosing of Saquinavir Plus Ritonavir in Hiv-1-infected Individuals (2001) (24)
A randomized, double-blind trial of half versus standard dose of zidovudine plus zalcitabine in Thai HIV-1-infected patients (study HIV-NAT 001) (2000) (24)
Pharmacokinetics of Stavudine and Didanosine Coadministered with Nelfinavir in Human Immunodeficiency Virus-Exposed Neonates (2001) (23)
Changes in cellular virus load and zidovudine resistance of syncytium-inducing and non-syncytium-inducing human immunodeficiency virus populations under zidovudine pressure: a clonal analysis. (1996) (23)
Dose‐Finding Study of a Once‐Daily Indinavir/Ritonavir Regimen (2000) (23)
Mortality and morbidity among HIV type-1-infected patients during the first 5 years of a multicountry HIV workplace programme in Africa (2009) (23)
Low number of functionally active B lymphocytes in the peripheral blood of HIV-1-seropositive individuals with low p24-specific serum antibody titers. (1991) (23)
Differences in clinical course in zidovudine-treated asymptomatic HIV-infected men associated with T-cell function at intake. (1991) (23)
Introducing a model of cardiovascular prevention in Nairobi's slums by integrating a public health and private-sector approach: the SCALE-UP study (2013) (22)
HIV-1 RNA response to antiretroviral treatment in 1280 participants in the Delta Trial: an extended virology study. (1999) (22)
Semen Quality and Drug Concentrations in Seminal Plasma of Patients Using a Didanosine or Didanosine Plus Tenofovir Containing Antiretroviral Regimen (2007) (22)
Rapid disease progression in human immunodeficiency virus type 1-infected individuals with adverse reactions to trimethoprim-sulfamethoxazole prophylaxis. (1997) (22)
"Test and treat": is it enough? (2011) (22)
Safety and Efficacy of Once-Daily Nevirapine Dosing: A Multicohort Study (2009) (22)
Does alcohol intake affect highly active antiretroviral therapy (HAART) response in HIV-positive patients? (2000) (22)
The DAD Study Group. Combination antiretroviral therapy and the risk of myocardial infarction (2003) (21)
Viral Replication Under Combination Antiretroviral Therapy: A Comparison of Four Different Regimens (2002) (21)
Frequent use of menfegol spermicidal vaginal foaming tablets associated with a high incidence of genital lesions. (1995) (21)
We Must Not Let Protestors Derail Trials of Pre-Exposure Prophylaxis for HIV (2005) (21)
Slower decline of plasma HIV-1 RNA following highly suppressive antiretroviral therapy in primary compared with chronic infection (2000) (21)
Evaluation of a second-generation nucleic acid sequence-based amplification assay for quantification of HIV type 1 RNA and the use of ultrasensitive protocol adaptations. (2000) (21)
Implantation of cultured thymic fragments in patients with acquired immunodeficiency syndrome. (1986) (20)
Dose‐Escalating Study of the Safety and Pharmacokinetics of Nelfinavir in HIV‐Exposed Neonates (2002) (20)
Safety and Effectiveness of Combination Antiretroviral Therapy during the First Year of Treatment in HIV-1 Infected Rwandan Children: A Prospective Study (2014) (20)
Antibody response to viral proteins U (vpu) and R (vpr) in HIV-1-infected individuals. (1990) (20)
Persistent human immunodeficiency virus type 1 antigenemia in children correlates with disease progression. (1988) (20)
The Pharmacokinetics of Nelfinavir in HIV-1—Infected Children (2002) (19)
Boosted versus Unboosted Indinavir with Zidovudine and Lamivudine in Nucleoside Pre-Treated Patients: A Randomized, Open-Label Trial with 112 Weeks of Follow-Up (HIV-Nat 005) (2006) (19)
Disseminated cat-scratch disease in a patient with AIDS. (1989) (18)
Markedly diminished lipolysis and partial restoration of glucose metabolism, without changes in fat distribution after extended discontinuation of protease inhibitors in severe lipodystrophic human immunodeficient virus-1-infected patients. (2004) (18)
Treatment as Prevention—Where Next? (2014) (18)
Plasma HIV-1 RNA Decline Within the First Two Weeks of Treatment Is Comparable for Nevirapine, Efavirenz, or Both Drugs Combined and Is Not Predictive of Long-Term Virologic Efficacy: A 2NN Substudy (2005) (18)
Brief Report: Stavudine but not Didanosine as Part of HAART Contributes to Peripheral Lipoatrophy: A Substudy from the Antiretroviral Regimen Evaluation Study (ARES) (2007) (18)
HIV-1 Autologous Antibody Neutralization Associates with Mother to Child Transmission (2013) (17)
Clinical significance of transient HIV type-1 viraemia and treatment interruptions during suppressive antiretroviral treatment (2010) (17)
Effects of nevirapine, compared with lamivudine, on lipids and lipoproteins in HIV-1-uninfected newborns: the stopping infection from mother-to-child via breast-feeding in Africa lipid substudy. (2007) (17)
Cytomegalovirus rather than HIV triggers the outgrowth of effector CD8+CD45RA+CD27− T cells in HIV-1-infected children (2005) (17)
Population Pharmacokinetics of Itraconazole in Thai HIV-1-Infected Persons (2003) (16)
Once-daily indinavir plus ritonavir: preliminary results of the PIPO study. (2000) (16)
No Virological Failure in Semen During Properly Suppressive Antiretroviral Therapy Despite Subtherapeutic Local Drug Concentrations (2006) (16)
Unrecognised tuberculosis at antiretroviral therapy initiation is associated with lower CD4+ T cell recovery (2012) (16)
Antiretroviral therapy in previously untreated adults infected with the human immunodeficiency virus type I: established and potential determinants of virological outcome. (2004) (16)
Pathogenicity and diversity of HIV and implications for clinical management: a review. (1994) (16)
Both R5 and X4 Human Immunodeficiency Virus Type 1 Variants Persist during Prolonged Therapy with Five Antiretroviral Drugs (2002) (16)
Development and evaluation of a patient centered cardiovascular health education program for insured patients in rural Nigeria (QUICK - II) (2011) (16)
HIV-related morbidity and mortality in sub-Saharan Africa: opportunities for prevention. (1993) (16)
Increasing cerebrospinal fluid chemokine concentrations despite undetectable cerebrospinal fluid HIV RNA in HIV-1-infected patients receiving antiretroviral therapy. (2000) (16)
Influenza-like syndrome in homosexual men: a prospective diagnostic study. (1988) (16)
Durable HIV-1 Suppression with Indinavir after Failing Lamivudine-Containing Double Nucleoside Therapy: A Randomized Controlled Trial (2001) (16)
Syngeneic leukocytes together with suramin failed to improve immunodeficiency in a case of transfusion-associated AIDS after syngeneic bone marrow transplantation (1988) (15)
Global response to HIV: treatment as prevention, or treatment for treatment? (2014) (15)
Lack of efficacy of low dose oral interferon alfa in symptomatic HIV-1 infection: a randomised, double blind, placebo controlled trial. (1998) (15)
Current HIV clinical trial design issues. (1995) (15)
Implementation and effect of intensified case finding on diagnosis of tuberculosis in a large urban HIV clinic in Uganda: a retrospective cohort study. (2012) (15)
Maximizing the benefits of antiretroviral therapy for key affected populations (2014) (15)
Soluble tumor necrosis factor receptors as surrogate markers for the assessment of zidovudine treatment in asymptomatic HIV-1 infection. (1995) (15)
A Rational Approach to the Selection and Sequencing of Nucleoside/Nucleotide Analogues: A New Paradigm (2000) (15)
North-South Corridor Demonstration Project: Ethical and Logistical Challenges in the Design of a Demonstration Study of Early Antiretroviral Treatment for Long Distance Truck Drivers along a Transport Corridor through South Africa, Zimbabwe, and Zambia (2013) (15)
A Randomized, Open‐Label, Comparative Trial of Zidovudine Plus Lamivudine Versus Zidovudine Plus Lamivudine Plus Didanosine in Antiretroviral‐Naive HIV‐1‐Infected Thai Patients (2001) (14)
Infection by zidovudine-resistant HIV-1 compromises the virological response to stavudine in a drug-naive patient. (2000) (14)
Confirmation of HIV seropositivity: Comparison of a novel radioimmunoprecipitation assay to immunoblotting and virus culture (1988) (14)
Dyslipidemia in an Asian Population After Treatment for Two Years With Protease Inhibitor-Containing Regimens (2007) (14)
Target organ damage among hypertensive adults in rural Nigeria: a cross-sectional study (2014) (14)
Reducing the boosting dose of ritonavir does not affect saquinavir plasma concentrations in HIV-1-infected individuals (2009) (13)
Persistence of Viral HLA-DR- CD4 T-Cell Reservoir during Prolonged Treatment of HIV-1 Infection with a Five-Drug Regimen (2002) (13)
Detection of late pp67-mRNA by NASBA in peripheral blood for the diagnosis of human cytomegalovirus disease in AIDS patients. (2002) (13)
Conversion rate towards a syncytium inducing (SI) phenotype during different stages of HIV infection and prognostic value of SI phenotype for survival after aids diagnoses (1997) (13)
Failure to maintain high-dose treatment regimens during long-term use of zidovudine in patients with symptomatic human immunodeficiency virus type 1 infection. (1990) (13)
Establishment of the CD 4 T-cell pool in healthy children and untreated children infected with HIV-1 (2004) (13)
The ADAM study continued: maintenance therapy after 50 weeks of induction therapy. (2001) (13)
Quality of life in maintenance vs prolonged induction therapy for HIV. (2000) (12)
Three-Year Durability of Dual-Nucleoside Versus Triple-Nucleoside Therapy in a Thai Population With HIV Infection (2004) (12)
Low antigenicity of HIV-1 rev: rev-specific antibody response of limited value as correlate of rev gene expression and disease progression. (1989) (12)
Long-term zidovudine treatment of asymptomatic HIV-1-infected subjects. (1990) (12)
Pharmacokinetics of Lower Doses of Saquinavir Soft-Gel Caps (800 and 1200 Mg Twice Daily) Boosted with Itraconazole in HIV-1-Positive Patients (2002) (12)
The 48‐week efficacy of once‐daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy (2005) (11)
Comprehensive longitudinal analysis of hepatitis C virus (HCV)‐specific T cell responses during acute HCV infection in the presence of existing HIV‐1 infection (2009) (11)
Clinical, virological and immunological features of primary HIV-1 infection. (1991) (11)
The boosting of didanosine by allopurinol permits a halving of the didanosine dosage (2002) (11)
Serological markers in HIV infection. (1988) (11)
Cervical and anal HPV infection: cytological and histological abnormalities in HIV-infected women in Thailand (2015) (11)
Clinical trials in Asia. (1998) (11)
CC chemokine receptor 5 delta32 and CC chemokine receptor 2 64I polymorphisms do not influence the virologic and immunologic response to antiretroviral combination therapy in human immunodeficiency virus type 1-infected patients. (2002) (11)
Cardiovascular prevention model from Kenyan slums to migrants in the Netherlands (2015) (11)
Cellular and humoral immunity in various cohorts of male homosexuals in relation to infection with human immunodeficiency virus. (1989) (11)
Viral decay dynamics in HIV-infected patients receiving ritonavir-boosted saquinavir and efavirenz with or without enfuvirtide: a randomized, controlled trial (HIV-NAT 012). (2006) (11)
Antibodies to an HIV-1 synthetic peptide with partial homology to MULV P15E do not protect against AIDS. (1989) (10)
[Primary infections with human immunodeficiency virus]. (1990) (10)
Rapid quantification of delavirdine, a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with fluorescence detection. (1999) (10)
Intravenous immunoglobulin (IVIG) treatment for modulation of immune activation in human immunodeficiency virus type 1 infected therapy-naive individuals. (2007) (10)
Does highly active antiretroviral therapy induce sickle cell crises? (2002) (10)
Use of composite end points to measure clinical events. (2003) (10)
Short communication: Aging not gender is associated with high atazanavir plasma concentrations in Asian HIV-infected patients. (2013) (10)
Introduction: International perspectives on antiretroviral resistance (2001) (10)
Short communication: No detrimental immunological effects of mycophenolate mofetil and HAART in treatment-naive acute and chronic HIV-1-infected patients. (2005) (9)
Public–private partnerships and new models of healthcare access (2008) (9)
Cultured human thymus epithelial monolayer cells induce CD4 expression on mononuclear cells of AIDS patients in vitro. (1986) (9)
Dynamics of the Pool of Infected Resting Cd4 Hla-Dr- T Lymphocytes in Patients Who Started a Triple Class Five-Drug Antiretroviral Regimen During Primary HIV-1 Infection (2002) (9)
Ketoconazole is inferior to ritonavir as an alternative booster for saquinavir in a once daily regimen in Thai HIV-1 infected patients (2007) (9)
Long-term follow-up of randomized trials of immediate versus deferred zidovudine in symptom-free HIV infection. Joint Concorde and Opal Coordinating Committee. (1998) (9)
Low versus High CD4 Cell Count as Starting Point for Introduction of Antiretroviral Treatment in Resource-Poor Settings: A Scenario-Based Analysis (2003) (9)
Antigen-driven CD 4 1 T cell and HIV-1 dynamics : Residual viral replication under highly active antiretroviral therapy (1999) (9)
HIV type 1 mother-to-child transmission facilitated by distinctive glycosylation sites in the gp120 envelope glycoprotein. (2012) (9)
Combination Antiretroviral Therapy (2012) (9)
Evaluation of nevirapine and/or hydroxyurea with nucleoside reverse transcriptase inhibitors in treatment-naive HIV-1-infected subjects (2004) (9)
The natural history of HIV infection in homosexual men (1987) (8)
Decline in Serum 25 Hydroxyvitamin D Levels in HIV–Hbv-Coinfected Patients after Long-Term Antiretroviral Therapy (2014) (8)
Temporary increase in serum beta 2-microglobulin during treatment with interferon-alpha for AIDS-associated Kaposi's sarcoma. (1990) (8)
[LAV/HTLV-III infection after a one-time sexual contact with an AIDS patient]. (1985) (8)
Changing therapy in HIV. (1996) (8)
A feasibility study of immediate versus deferred antiretroviral therapy in children with HIV infection (2008) (8)
A randomized, double-blind trial of half versus standard dose of zidovudine plus zalcitabine in Thai HIV-1-infected patients (study HIV-NAT 001). HIV Netherlands Australia Thailand Research Collaboration. (2000) (8)
Introducing a model of cardiovascular prevention in Nairobi's slums by integrating a public health and private-sector approach: the SCALE-UP study. (2013) (8)
Serum beta 2-microglobulin levels in asymptomatic HIV-1-infected subjects during long-term zidovudine treatment. (1991) (7)
Pharmacokinetics and 48-Week Safety and Efficacy of Generic Lopinavir/Ritonavir in Thai HIV-Infected Patients (2013) (7)
Seroconversion to HIV-1 rev- and tat-gene-encoded proteins. (1989) (7)
Results of long-term follow-up of HIV-infected patients treated with lamivudine monotherapy, followed by a combination of lamivudine and zidovudine. (1997) (7)
A Phase I/IIa Study with Succinylated Human Serum Albumin (Suc-HSA), a candidate HIV-1 Fusion Inhibitor (2007) (7)
Sande's HIV/AIDS Medicine: Medical Management of AIDS 2013: Second Edition (2012) (7)
Antigenic variation of the dominant gp41 epitope in Africa. (1993) (7)
Antiviral activity of HIV type 1 protease inhibitors nelfinavir and indinavir in vivo is not influenced by P-glycoprotein activity on CD4+ T cells. (2007) (7)
Strategies for rescue therapy. (1998) (7)
Estimates of the virological benefit of antiretroviral therapy are both assay‐ and analysis‐dependent (1998) (7)
Serologic and immunologic markers in the course of HIV-1 infection. (1991) (7)
Quantitative pp65-antigenemia assay for the prediction of human cytomegalovirus disease in HIV-infected patients. (1999) (7)
A randomized, open-label, comparative trial of zidovudine plus lamivudine versus zidovudine plus lamivudine plus didanosine in antiretroviral-naive HIV-1-infected Thai patients. (2001) (7)
Highly active antiretroviral therapy including protease inhibitors does not confer a unique CD4 cell benefit. The AVANTI and INCAS Study Groups. (2000) (6)
Viral dynamics after starting first-line HAART in HIV-1-infected children (2006) (6)
Relationships between Drug Exposure, Changes in Metabolic Parameters and Body Fat in HIV-Infected Patients Switched to a Nucleoside Sparing Regimen (2007) (6)
Clinical treatment: Overview (1992) (6)
International perspectives on antiretroviral resistance. Introduction. (2001) (6)
Opportunistic Diseases as Measure of Immunodeficiency in HIV Infection (1992) (6)
Persistence of human immunodeficiency virus antigenemia in patients with the acquired immunodeficiency syndrome treated with a reverse transcriptase inhibitor, suramin. Ten-patient case-control study. (1988) (6)
Significant differences between plasma HIV-1 RNA assays in HIV-1 subtype E infected patients treated with antiretroviral therapy. (2002) (6)
Computational models developed without a genotype for resource-poor countries predict response to HIV treatment with 82% accuracy (2009) (6)
Neither Branded Nor Generic Lopinavir/Ritonavir Produces Adequate Lopinavir Concentrations at a Reduced Dose of 200/50 mg Twice Daily (2012) (5)
Editorial commentary: Under the spell of the red queen. (2013) (5)
Coïnfectie met hepatitis-C-virus en HIV (2003) (5)
HIV-1 P24 antigenaemia does not predict time of survival in AIDS patients. (1990) (5)
Markers for progression to acquired immune deficiency syndrome and zidovudine treatment of asymptomatic patients. (1989) (5)
Syngeneic leukocytes together with suramin failed to improve immunodeficiency in a case of transfusion-associated AIDS after syngeneic bone marrow transplantation. (1988) (5)
Improved adipose tissue function with initiation of protease inhibitor-only ART (2016) (5)
Summary of the II international consensus symposium on combined antiviral therapy and implications for future therapies (1997) (5)
A comparison of serum HIV-1 RNA levels as measured by two quantitative assays in zidovudine-treated, asymptomatic, HIV-infected individuals. (1996) (4)
The HIV Netherlands Australia Thailand research collaboration: lessons from 7 years of clinical research (2004) (4)
Risk of Tuberculosis after Antiretroviral Treatment Initiation: A Comparison between Efavirenz and Nevirapine Using Inverse Probability Weighting (2013) (4)
Serum p24 antigen levels in untreated and zidovudine-treated HIV-1 infected subjects. (1990) (4)
[Coinfection with hepatitis C virus and HIV]. (2003) (4)
Reply to George and to Stapleton et al. Reply on: GB virus C coinfection and HIV-1 disease progression: The Amsterdam Cohort Study J Infect Dis. 2005 Mar 1;191(5):678-85 (2005) (4)
[Pneumocystis carinii infection during prophylaxis with nebulized pentamidine in a patient with AIDS]. (1991) (4)
Thrombocytopenic purpura as first manifestation of human immunodeficiency virus type I (HIV-1) infection. (1990) (4)
Kaposi's sarcoma and AIDS (1990) (4)
Predictive value for survival of soluble tumor necrosis factor receptors p55 and p75 during zidovudine-containing treatment in symptomatic human immunodeficiency virus type 1 infection. (1996) (4)
Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection Marieke den Brinker a , Ferdinand W. N. M. Wit a , (2000) (4)
Nevirapine plus didanosine: once or twice daily combination? (2000) (3)
Temporary Treatment during Primary HIV Infection Does Not Affect Virologic Response to Subsequent Long-Term Treatment (2014) (3)
Reduced Prevalence of the CCR 5 D 32 Heterozygous Genotype in Human Immunodeficiency Virus – Infected Individuals with AIDS Dementia Complex (1999) (3)
Introduction 15 million on ART by 2015: a realistic target or just a dream. (2013) (3)
Prioritising access to antiretroviral therapy in resource-poor settings. (2002) (3)
Correlation of HIV core antigen, antibody and immune complex levels in sera of HIV-infected individuals. (1990) (3)
Retroviruses & Opportunistic Infections ‘99 (1999) (3)
The Limitations of Simplicity (1998) (3)
Combination antiretroviral therapy. Back to the future. (1995) (3)
CC chemokine receptor 5 delta 32 and CC chemokine receptor 2 64 I polymorphisms do not influence the virologic and immunologic response to antiretroviral combination therapy in human immunodeficiency virus type 1-infected patients (2002) (2)
Immunological analysis of treatment interruption after early highly active antiretroviral therapy. (2010) (2)
Access for All? (2004) (2)
Antiretroviral treatment: state of the art and future directions. (1991) (2)
Antiretroviral therapy and resistance to antiretroviral drugs. (2002) (2)
No detrimental immunological effects of mycophenolate mofetil and HAART in treatment-naive acute and chronic HIV-1-infected patients (2007) (2)
World Health Organization Public Health Approaches to Expand Antiretroviral Treatment Public Health Approaches to Expand Antiretroviral Treatment (2003) (2)
Combination Antiretroviral Therapy for HIV in Rwandan Adults: Clinical Outcomes and Impact on Reproductive Health up to 24 Months (2015) (2)
Implementation of TasP: challenges and opportunities (2014) (2)
Rapid expansion of access to antiretroviral therapy (ART). (2004) (2)
Quality of Life in Maintenance vs Prolonged Induction Therapy for HIV (2000) (2)
Protease inhibitors and non-nucleoside reverse transcriptase inhibitors have a comparable effect on the CD4 cell change after switching to tenofovir-based regimens. (2005) (2)
The prevalence of human immunodeficiency virus among pregnant women attending a hospital in the Moungo district, Cameroon. (1989) (2)
[HIV-1 therapy in the Netherlands; virological and immunological response to antiretroviral therapy]. (2001) (2)
[The use of the non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz in the treatment of patients with a chronic HIV-I infection]. (2006) (1)
[Early treatment with zidovudine; a turning point in the campaign against AIDS?]. (1989) (1)
CHAPTER 12 – New HIV Drug Development (2007) (1)
Pharmacokinetic Profiles of Nevirapine and Indinavir in Various Fractions of Seminal Plasma (2002) (1)
Session A: Natural history of HIV disease and predictors of clinical outcome. (1998) (1)
Scaling up access to HIV prevention, treatment, and care in resource-poor settings: challenges and opportunities (2006) (1)
Highlights of the Fourth International Workshop on HIV Drug Resistance. (1995) (1)
Serodiagnostic profiles of HIV and HIV pathogenesis in vivo. (1988) (1)
Impact Evaluation of HIF-supported Health Insurance Projects in Kenya: Dairy Farmers, Baseline Report (2011) (1)
World Bank meeting concludes drug resistance should not prevent distribution of antiretroviral therapy to poor countries (2003) (1)
WITHDRAWN: Loss of control of viremia in HIV-1 seroconverters with best prognosis and lowest viral load at setpoint (2002) (1)
HIV in Asia: the way forward (2009) (1)
A clinician's perspective: when to start antiretroviral treatment and when to change therapy. (1995) (1)
Original article Lack of eYcacy of low dose oral interferon alfa in symptomatic HIV-1 infection: a randomised, double blind, placebo controlled trial (1998) (1)
CHAPTER 54 – Antiretroviral Therapy in Resource-poor Settings: Challenges, Research Priorities, Opportunities (2008) (1)
Ki-67 expression and apoptosis in CD8+CD28+ and in CD8+CD28-T cells, naive, memory and effector CD8+ T cells in HIV-1-infection (1997) (0)
[Virological evaluation of treating HIV-infected patients with (combinations of) antiretroviral drugs at the Amsterdam Academic Medical Center, 1996/'97]. (1998) (0)
Antiretroviral Therapy after HIV Treatment with Highly Active T Cells + and CD 8 + Antigen-Specific CD 4 Reconstitution of EBV Latent but Not Lytic (2005) (0)
Cultured humanthymus epithelial monolayer cells induce CD4expression onmononuclear cells ofAIDSpatients invitro (1986) (0)
[Decrease in human immunodeficiency virus antigen levels in the cerebrospinal fluid during zidovudine treatment in patients with AIDS]. (1988) (0)
Mechanisms of decreasing HIV-1 specific CD 8 + T cell activity during progression to AIDS (2007) (0)
Additive or sequential nucleoside analogue therapy compared with continued zidovudine monotherapy in human immunodeficiency virus-infected patients with advanced disease does not prolong survival: an observational study. (1997) (0)
Chapter 4 " Durable HIV-1-suppression with indinavir after failing lamivudine containing double nucleoside therapy : a randomized controlled trial " (2012) (0)
High-Dos eNevirapin ei nPreviousl yUntreate dHuma nImmunodeficienc yVirus Typ e1-Infecte dPerson sDoe sNo tResul ti nSustaine dSuppressio no fViral Replication (1997) (0)
infected children Establishment of the CD4+ T cell pool in healthy and untreated HIV-1 (2013) (0)
Optimising HIV Treatment - Building on Experience - Based on a Symposium held Friday 15 March 2002, Seville, Spain - Introduction (2003) (0)
Promoting Rational and Evidence-based Use of Antiretroviral Therapies HIV-NAT (2006) (0)
[Possibilities of surgical cancer treatment]. (1985) (0)
Clinical and pharmacological aspects of induction-maintenance therapy in HIV-1 positive patients : the ADAM study (2007) (0)
AIDS 92/93. Clinical treatment: overview. (1993) (0)
MINIREVIEW P Glycoprotein in Human Immunodeﬁciency Virus Type 1 Infection and Therapy (2004) (0)
[Primary HIV-infection: infectious mononucleosis-like presentation with treatment options]. (1999) (0)
From AIDS to Global Health to Impact (2014) (0)
Comprar Sande's HIV/ AIDS Medicine, 2nd Edition | Nelson Sewankambo | 9781455706952 | Saunders (2011) (0)
UvA-DARE (Digital Academic Repository) Functional T cell reconstruction and human immunodeficiency virus-1-specific cell-mediated immunity during highly active antiretroviral therapy (1999) (0)
Since the discovery of HIV as the causative agent of AIDS in 1983/1984, remarkable progress (2014) (0)
The socio-economic and bio-medical impact of the introduction of affordable health insurances (including AIDS treatment) in Namibia (2006) (0)
HIV Type 1 Mother-to-Child Transmission Facilitated by Distinctive Glycosylation Sites in the gp 120 Envelope Glycoprotein (2012) (0)
[Lipodystrophy and 'buffalo hump' during treatment with HIV protease inhibitors]. (1998) (0)
Lack of e Y cacy of low dose oral interferon alfa in symptomatic HIV-1 infection : a randomised , double blind , placebo controlled trial (1998) (0)
Antiviral Therapy in 2003 (2001) (0)
UvA-DARE ( Digital Academic Repository ) Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral-Therapy-Naive Patients Infected with HIV-1 (2017) (0)
red blood cell transfusion and furosemide in cardiac surgery : friend or foe ? (2012) (0)
eJIAS: The Journal of HIV/AIDS Science and Medicine in the Developing World (2004) (0)
Biological Phenotype ofHumanImmunodeficiency VirusType1 Clones atDifferent Stages ofInfection: Progression ofDisease IsAssociated with a Shift fromMonocytotropic to T-Cell-Tropic VirusPopulations (1992) (0)
No effect of interleukin-2 on IgE levels given in addition to antiretroviral therapy in HIV-infected adults with CD4 >300 cells/mm3. (2005) (0)
Brief Report: Pharmacokinetics of Once‐Daily Saquinavir Hard‐Gelatin Capsules and Saquinavir Soft‐Gelatin Capsules Boosted With Ritonavir in HIV‐1‐Infected Subjects (2003) (0)
Use of chloroquine in reducing mother to child transmission of HIV-1 during breastfeeding (2009) (0)
UvA-DARE (Digital Academic Repository) CC chemokine receptor 5 delta32 and CC chemokine receptor 2 64I polymorphisms do not influence the virologic and immunologic response to antiretroviral combination therapy in human immunodeficiency virus type 1-infected patients (2002) (0)
Induction–maintenance antiretroviral therapy (1998) (0)
Designing an Institute for Health and Technology: The Amsterdam Living Lab (2014) (0)
Combination Antiretroviral Therapy for HIV Infection. Proceedings of an international symposium. Berlin, Germany, March 25-26, 1995. (1995) (0)
Overcoming therapeutic challenges : resistance, intolerance, end-points : satellite symposium to the Fifth European Conference on Clinical Aspects and Treatment of HIV Infection (1995) (0)
Estimating maternal care costs within the HCHP in rural Nigeria: a hospital-based study (2013) (0)
Anti-Retroviral Therapy and Resistance to Anti-Retroviral Drugs (2000) (0)
Loss of EBV-Specific CD4 + T Cells during Progression to EBV-Related AIDS Non-Hodgkin Lymphoma: Restoration by Highly Active Antiretroviral Therapy (HAART). (2004) (0)
Herpes simplex virus Type 2 and other genital ulcerative infections as a risk factor for HIV-1 acquisltion (2005) (0)
Tolerability and activity of a new recombinant interferon-alpha B/D hybrid in patients with HIV-1 infection. (1996) (0)
Consensus symposium on combined antiviral therapy. International Society for Antiviral Research and the National Institutes of Allergy and Infectious Diseases. (1996) (0)
UvA-DARE ( Digital Academic Repository ) A prospective , randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection (2005) (0)
We-P11:250 Effects of nevirapine as compared to lamivudine on lipids and lipoproteins in HIV-1 uninfected newborns: The simba lipid substudy (2006) (0)
Antiretroviral treatment and care of HIV (2007) (0)
The development of neural networks to predict virologic response to combination HIV therapy (2007) (0)
CONCISE COMMUNICATIONS Reduced Prevalence of the CCR5 D32 Heterozygous Genotype in Human Immunodeficiency Virus-Infected Individuals with AIDS Dementia Complex (1999) (0)
Full adherence to HAART: is it really necessary? (2002) (0)
P43 Rises in the CD4 cell count prior to anti-HIV treatment: Consequences for trial design? (1995) (0)
CHAPTERR 4 IMPROVEDD LONG-TERM SUPPRESSION OF HIV-1 REPLICATIONN WITH A TRIPLE-CLASS MULTIDRUGG REGIMEN COMPARED TO STANDARDD OF CARE ANTIRETROVIRAL THERAPY Y (2007) (0)
The clinical significance of the biological phenotype of HIV. (1993) (0)
Chloroquine Administration in Breastfeeding Mothers Associates with Increased HIV-1 Plasma Viral Loads (2020) (0)
HIV-NAT Promoting Rational and Evidence-based Use of Antiretroviral Therapies (2006) (0)
The pharmacokinetics of didanosine are equivalent in a once daily and twice daily regimen (1998) (0)
[Amsterdam duration of antiretroviral medication (ADAM)--study: induction-suppression treatment in HIV-I infection, preliminary results]. (1998) (0)
UvA-DARE ( Digital Academic Repository ) Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral-Therapy-Naive Patients Infected with HIV (2004) (0)
HHV8 ANTIBODY SEROPOSITIVITY IS PREDICTIVE OF KS DEVELOPMENT IN HIV-1 INFECTED INDIVIDUALS. (1998) (0)
Methodological standards in non-inferiority AIDS trials: moving from adherence to compliance: Response (2007) (0)
Time to move on HIV/AIDS treatment and care. (2003) (0)
Mitochondrial toxicities and metabolic complications in antiretroviral therapy. (2000) (0)

This paper list is powered by the following services:

Other Resources About Joep Lange

en.wikipedia.org

What Schools Are Affiliated With Joep Lange?

Joep Lange is affiliated with the following schools:

Image Attributions

Image Source for Joep Lange